APA (7th ed.) Citation

Rejdak, K., Zasybska, A., Pietruczuk, A., Baranowski, D., Szklener, S., Kaczmarek, M., & Stelmasiak, Z. (2021). Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study. MDPI AG.

Chicago Style (17th ed.) Citation

Rejdak, Konrad, Adriana Zasybska, Aleksandra Pietruczuk, Dariusz Baranowski, Sebastian Szklener, Magda Kaczmarek, and Zbigniew Stelmasiak. Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study. MDPI AG, 2021.

MLA (8th ed.) Citation

Rejdak, Konrad, et al. Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study. MDPI AG, 2021.